https://www.thebodypro.com/category/rilpivirine-edurant

Rilpivirine (Edurant)

The Latest

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies Img
News

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

Dual Maintenance Therapy With Dolutegravir + Rilpivirine Img
News Analysis

Dual Maintenance Therapy With Dolutegravir + Rilpivirine

In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.

Anton Pozniak at the 90-90-90 Targets Workshop
News

How Will Long-Acting HIV Antiretrovirals Work in the Real World?

Once viable long-acting HIV prevention and treatment options have reached the market, what will be their true impact? Leading HIV clinician-researcher Anton Pozniak, M.D., shares his expertise.

Promo Image
CROI (Conference on Retroviruses and Opportunistic Infections)

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

Two-Drug HIV Treatment Regimens Effective in Latest Studies Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Two-Drug HIV Treatment Regimens Effective in Latest Studies

"This is really the first step in demonstrating that two-drug regimens can be as effective as three-drug regimens," says Kimberly Smith, M.D., M.P.H.

Single Injected Dose of Long-Acting Rilpivirine Inhibits HIV in Rectal Tissue Img
News

Single Injected Dose of Long-Acting Rilpivirine Inhibits HIV in Rectal Tissue

A single intramuscular dose of long-acting rilpivirine (Edurant) significantly lowered HIV in rectal tissue but not in vaginal or cervical tissue, according to a recent study.

Rilpivirine as HIV PrEP Remains in Body 18 Months After Single Long-Acting Shot Img
Conference Coverage

Rilpivirine as HIV PrEP Remains in Body 18 Months After Single Long-Acting Shot

Rilpivirine (Edurant) remained detectable in plasma and female genital tract fluids for 18 months or more after a single injection of a long-acting non-nucleoside for HIV pre-exposure prophylaxis (PrEP).

Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results Img
News

Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results

Rilpivirine (Edurant) plus ritonavir-boosted darunavir (Prezista) as HIV maintenance therapy compared similarly to a three-drug regimen of a boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors, according to a study presente...

Pharmacokinetics of Antiretrovirals in Pregnancy: Rilpivirine, Etravirine and Raltegravir Img
Conference Coverage

Pharmacokinetics of Antiretrovirals in Pregnancy: Rilpivirine, Etravirine and Raltegravir

Three posters at CROI 2015 described pharmacokinetics of antiretrovirals in pregnancy for rilpivirine, etravirine and raltegravir. None of the studies suggested that dose adjustment is required.

Promo Image
IDWeek

HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.